MedTrace Logo

Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®

NCT04313270 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2021-03-08

No results posted yet for this study

Summary

Protein convertase subtilisin kexin type 9 (PCSK-9) inhibitors demonstrated efficacy in cholesterol reduction and in the prevention of cardiovascular events. The investigators will evaluate changes in lipid profile, oxidation markers and subclinical atherosclerosis in patients with familial hypercholesterolemia (FH) during 12 weeks of treatment with a PCSK-9 inhibitor, Evolocumab®.

Conditions

  • Hypercholesterolemia, Familial

Interventions

DRUG

Evolocumab

12 weeks of treatment with Evolocumab

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2022-12-01
Completion
2025-12-01
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04313270 on ClinicalTrials.gov